早期联合免疫抑制可能对老年克罗恩病患者有效且安全:REACT试验的事后分析
该REACT试验事后分析比较了早期联合免疫抑制与常规管理在<60岁和≥60岁克罗恩病患者中的疗效与安全性。24个月时,两组年龄层的主要不良结局风险和激素-free临床缓解率均无显著差异,早期联合免疫抑制在老年患者中可能可作为治疗选择。
要点
- 老年(≥60岁)克罗恩病患者中,早期联合免疫抑制与常规管理相比,主要不良结局和安全性无显著差异。
- 早期联合免疫抑制在年轻和老年患者中的疗效(激素-free临床缓解、主要不良结局时间)无显著交互作用。
- 作者认为,对于疾病控制欠佳的特定老年克罗恩病患者,早期联合免疫抑制可考虑作为一种治疗选择。
核心结论
- 在年轻和老年患者中,早期联合免疫抑制与常规管理相比,疗效和安全性无差异。
- 作者认为,对于疾病控制欠佳的特定老年克罗恩病患者,早期联合免疫抑制可考虑作为一种治疗选择。
研究设计与样本
- REACT试验的事后分析,该试验为集群随机试验。
- 共纳入1981例患者,其中311例(15.7%)≥60岁;老年患者中173例随机分配至早期联合免疫抑制组,138例分配至常规管理组。
- 比较24个月时的疗效(主要不良结局时间:克罗恩病相关手术、住院或严重并发症;激素-free临床缓解)和安全性结局,使用Cox比例风险分析或改良Poisson模型。
- 早期联合免疫抑制组中,皮质类固醇治疗4-12周内未达到临床缓解的患者接受肿瘤坏死因子-α拮抗剂联合抗代谢药物治疗,并按逐步算法序贯升级。
主要发现
- 老年患者中,24个月内10%发生克罗恩病相关并发症(早期联合免疫抑制 vs 常规管理:6.4% vs 14.5%),14例死亡(3.5% vs 5.8%)。
- 激素-free临床缓解率:<60岁患者中,早期联合免疫抑制(72.6%)vs 常规管理(64.4%),相对风险(RR)1.06(95% CI 0.98-1.15);≥60岁患者中,早期联合免疫抑制(74.8%)vs 常规管理(63.0%),RR 1.09(95% CI 0.90-1.33),交互作用P=0.78。
- 主要不良结局时间:<60岁患者中,早期联合免疫抑制 vs 常规管理的风险比(HR)0.71(95% CI 0.53-0.96);≥60岁患者中,HR 0.69(95% CI 0.31-1.51),交互作用P=0.92。
临床怎么用
- 作者认为,对于疾病控制欠佳的特定老年克罗恩病患者,早期联合免疫抑制可考虑作为一种治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Physicians may be reluctant to prescribe combined immunosuppression in older patients with Crohn's disease due to perceived risk of treatment-related complications. AIM: To evaluate the impact of age on risk of Crohn's disease-related complications in patients treated with early combined immunosuppression vs conventional management in a post hoc analysis of the randomised evaluation of an algorithm for Crohn's treatment (REACT), a cluster-randomised trial. METHODS: We compared efficacy (time to major adverse outcome of Crohn's disease-related surgery, hospitalisation or serious complications; corticosteroid-free clinical remission) and safety outcomes at 24 months, between patients aged <60 vs ≥60 years randomised to early combined immunosuppression or conventional management, using Cox proportional hazard analysis or modified Poisson model. In the early combined immunosuppression arm, patients with failure to achieve clinical remission within 4-12 weeks of corticosteroids were treated with a combination of tumour necrosis factor-α antagonist plus anti-metabolite and sequentially escalated in a stepwise algorithm. RESULTS: Of 1981 patients, 311 were ≥60 years (15.7%; 173 randomised to early combined immunosuppression and 138 to conventional management). Over 24 months, 10% of older patients developed Crohn's disease-related complications (early combined immunosuppression vs conventional management: 6.4% vs 14.5%) and 14 patients died (3.5% vs 5.8%). There was no difference between younger and older patients in risk of achieving corticosteroid-free clinical remission (<60 years, early combined immunosuppression (72.6%) vs conventional management (64.4%): relative risk [RR], 1.06 [95% CI, 0.98-1.15] vs ≥60 years, early combined immunosuppression (74.8%) vs conventional management (63.0%): RR, 1.09 [0.90-1.33], P-interaction = 0.78) or time to major adverse outcome (<60 years: hazard ratio [HR], 0.71 [0.53-0.96] vs ≥60 years: HR, 0.69 [0.31-1.51], P-interaction = 0.92) with early combined immunosuppression vs conventional management. CONCLUSIONS: We observed no difference in efficacy and safety of early combined immunosuppression compared to conventional management in older and younger patients. Early combined immunosuppression may be considered as a treatment option in selected older patients with Crohn's disease with suboptimal disease control. Clinical Trial Identifier: NCT01030809.
引用
- Singh S, Stitt LW, Zou G, et al. Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019. PMID: 30891808. doi:10.1111/apt.15214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。